Candel Therapeutics (CADL) Asset Utilization Ratio (2021 - 2022)
Candel Therapeutics recorded quarterly Asset Utilization Ratio of 0.0 in Q4 2022, up 37.27% quarter-over-quarter from 0.0 in Q3 2022, and up 42.55% year-over-year from 0.0 in Q4 2021.
Candel Therapeutics' Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.0 for Q4 2022.
- In Q4 2022, Asset Utilization Ratio rose 42.55% year-over-year to 0.0; the TTM figure through Dec 2022 stood at 0.0 (up 42.55% YoY), while the FY2022 annual figure was 0.0, down 4.52% from the prior year.
- Asset Utilization Ratio came in at 0.0 for Q4 2022 at Candel Therapeutics, up from 0.0 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.0 in Q3 2021 to a low of 0.0 in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | 0.00 |
| Jun 30, 2022 | 0.00 |
| Mar 31, 2022 | 0.00 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | 0.00 |